Genenta Science receives Nasdaq minimum bid price deficiency notice
GNTA•Genenta Science received a Nasdaq notice on October 16, 2026, after its ADSs traded below $1.00 for 30 consecutive business days. It has until April 14, 2027, to meet the requirement, with a possible additional 180-day extension.
1. Compliance period
Genenta Science said its ADSs traded below $1.00 from September 3 through October 15, 2026. Trading continues without immediate delisting, and the initial 180-calendar-day compliance period ends April 14, 2027; the ADSs must close at $1.00 or higher for at least 10 consecutive business days.
2. Possible measures
An additional 180-calendar-day extension may be available if the company meets other listing standards and provides written notice of its plans to cure the deficiency. Shareholders have authorized a reverse stock split ranging from 1-for-10 to 1-for-20, which the board may implement.
